Patient, donor, and graft characteristics
| Characteristic . | HD-PTCy . | ID-PTCy . | . | All patients . |
|---|---|---|---|---|
| DL1 . | DL2 . | DL3 . | ||
| 50 mg/kg per day . | 25 mg/kg per day . | 25 mg/kg . | ||
| Days +3/+4 . | Days +3/+4 . | Day +4 . | ||
| (n = 5) . | (n = 23) . | (n = 7) . | (N = 35) . | |
| Age, median (range), y | ||||
| Recipient | 25 (21-38) | 34 (18-57) | 23 (20-30) | 28 (18-57) |
| Donor | 42 (23-49) | 31 (17-54) | 43 (29-52) | 38 (17-54) |
| Male sex, n (%) | ||||
| Recipient | 3 (60) | 14 (61) | 3 (43) | 20 (57) |
| Donor | 2 (40) | 17 (74) | 3 (43) | 22 (63) |
| Race or ethnic group, n (%) | ||||
| White, Non-Hispanic | 0 (0) | 3 (13) | 1 (14) | 4 (11) |
| White, Hispanic | 5 (100) | 15 (65) | 2 (29) | 22 (63) |
| African American | 0 (0) | 1 (4) | 1 (14) | 2 (6) |
| Asian | 0 (0) | 0 (0) | 1 (14) | 1 (3) |
| American Indian/Alaskan Native | 0 (0) | 1 (4) | 1 (14) | 2 (6) |
| Multiracial | 0 (0) | 3 (13) | 1 (14) | 4 (11) |
| Karnofsky performance status, n (%) | ||||
| 100% | 2 (40) | 5 (22) | 1 (14) | 8 (23) |
| 90% | 1 (20) | 14 (61) | 4 (57) | 19 (54) |
| <90% | 2 (40) | 4 (17) | 2 (29) | 8 (23) |
| Comorbidity index (HCT-CI), n (%) | ||||
| 0 | 0 (0) | 2 (9) | 2 (29) | 4 (11) |
| 1-2 | 0 (0) | 8 (35) | 1 (14) | 9 (26) |
| 3-4 | 2 (40) | 8 (35) | 1 (14) | 11 (31) |
| ≥5 | 3 (60) | 5 (22) | 3 (43) | 11 (31) |
| Disease, n (%) | ||||
| Acute myeloid leukemia | 1 (20) | 5 (22) | 3 (43) | 9 (26) |
| Acute lymphoblastic leukemia | 3 (60) | 10 (43) | 2 (29) | 15 (43) |
| Myelodysplastic syndrome | 0 (0) | 0 (0) | 1 (14) | 1 (3) |
| Chronic myelogenous leukemia | 0 (0) | 1 (4) | 0 (0) | 1 (3) |
| Primary myelofibrosis | 0 (0) | 2 (9) | 0 (0) | 2 (6) |
| Non-Hodgkin lymphoma | 1 (20) | 3 (13) | 0 (0) | 4 (11) |
| Hodgkin lymphoma | 0 (0) | 2 (9) | 1 (14) | 3 (9) |
| Diagnosis to transplant, median (range), y | 1.0 (0.4-8.5) | 2.0 (0.4-14.7) | 1.1 (0.2-2.6) | 1.7 (0.2-14.7) |
| Prior lines of therapy, median (range), n | 3 (2-8) | 3 (1-10) | 3 (1-6) | 3 (1-10) |
| Disease status at transplant, n (%) | ||||
| CR1, MRD (−) | 2 (40) | 7 (30) | 4 (57) | 13 (37) |
| CR1, MRD (+) | 1 (20) | 1 (4) | 0 (0) | 2 (6) |
| CR ≥ 2, MRD (−) | 1 (20) | 8 (35) | 2 (29) | 11 (31) |
| CR ≥ 2, MRD (+) | 0 (0) | 2 (9) | 0 (0) | 2 (6) |
| SD | 0 (0) | 2 (9) | 1 (14) | 3 (9) |
| PD | 1 (20) | 3 (13) | 0 (0) | 4 (11) |
| Disease Risk Index (refined), n (%) | ||||
| Low | 0 (0) | 2 (9) | 1 (14) | 3 (9) |
| Intermediate | 3 (60) | 11 (48) | 2 (29) | 16 (46) |
| High/very high | 2 (40) | 10 (43) | 4 (57) | 16 (46) |
| CMV seropositive, n (%) | ||||
| Recipient | 4 (80) | 17 (74) | 6 (86) | 27 (77) |
| Donor | 5 (100) | 18 (78) | 7 (100) | 30 (86) |
| ABO matching, n (%) | ||||
| Matched | 4 (80) | 16 (70) | 6 (86) | 26 (74) |
| Minor mismatch | 1 (20) | 4 (17) | 0 (0) | 5 (14) |
| Major mismatch | 0 (0) | 2 (9) | 0 (0) | 2 (6) |
| Bidirectional mismatch | 0 (0) | 1 (4) | 1 (14) | 2 (6) |
| GVH HLA matching, n (%) | ||||
| 5/10 | 3 (60) | 12 (52) | 5 (71) | 20 (57) |
| 6/10 | 2 (40) | 6 (26) | 2 (29) | 10 (29) |
| 7/10 | 0 (0) | 2 (9) | 0 (0) | 2 (6) |
| 8/10 | 0 (0) | 2 (9) | 0 (0) | 2 (6) |
| 10/10 | 0 (0) | 1 (4) | 0 (0) | 1 (3) |
| HVG HLA matching, n (%) | ||||
| 5/10 | 2 (40) | 14 (61) | 4 (57) | 20 (57) |
| 6/10 | 2 (40) | 4 (17) | 2 (29) | 8 (23) |
| 7/10 | 1 (20) | 3 (13) | 1 (14) | 5 (14) |
| 8/10 | 0 (0) | 2 (9) | 0 (0) | 2 (6) |
| Female into male, n (%) | 2 (40) | 3 (13) | 2 (29) | 7 (20) |
| Donor relation, n (%) | ||||
| Father | 2 (40) | 2 (9) | 2 (29) | 6 (17) |
| Mother | 1 (20) | 2 (9) | 2 (29) | 5 (14) |
| Brother | 0 (0) | 7 (30) | 0 (0) | 7 (20) |
| Sister | 2 (40) | 2 (9) | 2 (29) | 6 (17) |
| Son | 0 (0) | 6 (26) | 0 (0) | 6 (17) |
| Daughter | 0 (0) | 1 (4) | 0 (0) | 1 (3) |
| Cousin (male) | 0 (0) | 1 (4) | 1 (14) | 2 (6) |
| Cousin (female) | 0 (0) | 1 (4) | 0 (0) | 1 (3) |
| Nephew | 0 (0) | 1 (4) | 0 (0) | 1 (3) |
| Infused cell dose, median (range) | ||||
| Total nucleated cells (108/kg) | 5.6 (3.6-6.6) | 4.7 (1.8-9.5) | 4.3 (2.8-6.6) | 4.7 (1.8-9.5) |
| CD34+ cells (106/kg) | 7.4 (2.8-8.2) | 5.1 (2.6-11.3) | 3.9 (3.0-7.2) | 4.8 (2.6-11.3) |
| CD3+ cells (107/kg) | 3.9 (3.1-4.0) | 3.3 (1.9-6.7) | 3.7 (2.3-4.9) | 3.4 (1.9-6.7) |
| Characteristic . | HD-PTCy . | ID-PTCy . | . | All patients . |
|---|---|---|---|---|
| DL1 . | DL2 . | DL3 . | ||
| 50 mg/kg per day . | 25 mg/kg per day . | 25 mg/kg . | ||
| Days +3/+4 . | Days +3/+4 . | Day +4 . | ||
| (n = 5) . | (n = 23) . | (n = 7) . | (N = 35) . | |
| Age, median (range), y | ||||
| Recipient | 25 (21-38) | 34 (18-57) | 23 (20-30) | 28 (18-57) |
| Donor | 42 (23-49) | 31 (17-54) | 43 (29-52) | 38 (17-54) |
| Male sex, n (%) | ||||
| Recipient | 3 (60) | 14 (61) | 3 (43) | 20 (57) |
| Donor | 2 (40) | 17 (74) | 3 (43) | 22 (63) |
| Race or ethnic group, n (%) | ||||
| White, Non-Hispanic | 0 (0) | 3 (13) | 1 (14) | 4 (11) |
| White, Hispanic | 5 (100) | 15 (65) | 2 (29) | 22 (63) |
| African American | 0 (0) | 1 (4) | 1 (14) | 2 (6) |
| Asian | 0 (0) | 0 (0) | 1 (14) | 1 (3) |
| American Indian/Alaskan Native | 0 (0) | 1 (4) | 1 (14) | 2 (6) |
| Multiracial | 0 (0) | 3 (13) | 1 (14) | 4 (11) |
| Karnofsky performance status, n (%) | ||||
| 100% | 2 (40) | 5 (22) | 1 (14) | 8 (23) |
| 90% | 1 (20) | 14 (61) | 4 (57) | 19 (54) |
| <90% | 2 (40) | 4 (17) | 2 (29) | 8 (23) |
| Comorbidity index (HCT-CI), n (%) | ||||
| 0 | 0 (0) | 2 (9) | 2 (29) | 4 (11) |
| 1-2 | 0 (0) | 8 (35) | 1 (14) | 9 (26) |
| 3-4 | 2 (40) | 8 (35) | 1 (14) | 11 (31) |
| ≥5 | 3 (60) | 5 (22) | 3 (43) | 11 (31) |
| Disease, n (%) | ||||
| Acute myeloid leukemia | 1 (20) | 5 (22) | 3 (43) | 9 (26) |
| Acute lymphoblastic leukemia | 3 (60) | 10 (43) | 2 (29) | 15 (43) |
| Myelodysplastic syndrome | 0 (0) | 0 (0) | 1 (14) | 1 (3) |
| Chronic myelogenous leukemia | 0 (0) | 1 (4) | 0 (0) | 1 (3) |
| Primary myelofibrosis | 0 (0) | 2 (9) | 0 (0) | 2 (6) |
| Non-Hodgkin lymphoma | 1 (20) | 3 (13) | 0 (0) | 4 (11) |
| Hodgkin lymphoma | 0 (0) | 2 (9) | 1 (14) | 3 (9) |
| Diagnosis to transplant, median (range), y | 1.0 (0.4-8.5) | 2.0 (0.4-14.7) | 1.1 (0.2-2.6) | 1.7 (0.2-14.7) |
| Prior lines of therapy, median (range), n | 3 (2-8) | 3 (1-10) | 3 (1-6) | 3 (1-10) |
| Disease status at transplant, n (%) | ||||
| CR1, MRD (−) | 2 (40) | 7 (30) | 4 (57) | 13 (37) |
| CR1, MRD (+) | 1 (20) | 1 (4) | 0 (0) | 2 (6) |
| CR ≥ 2, MRD (−) | 1 (20) | 8 (35) | 2 (29) | 11 (31) |
| CR ≥ 2, MRD (+) | 0 (0) | 2 (9) | 0 (0) | 2 (6) |
| SD | 0 (0) | 2 (9) | 1 (14) | 3 (9) |
| PD | 1 (20) | 3 (13) | 0 (0) | 4 (11) |
| Disease Risk Index (refined), n (%) | ||||
| Low | 0 (0) | 2 (9) | 1 (14) | 3 (9) |
| Intermediate | 3 (60) | 11 (48) | 2 (29) | 16 (46) |
| High/very high | 2 (40) | 10 (43) | 4 (57) | 16 (46) |
| CMV seropositive, n (%) | ||||
| Recipient | 4 (80) | 17 (74) | 6 (86) | 27 (77) |
| Donor | 5 (100) | 18 (78) | 7 (100) | 30 (86) |
| ABO matching, n (%) | ||||
| Matched | 4 (80) | 16 (70) | 6 (86) | 26 (74) |
| Minor mismatch | 1 (20) | 4 (17) | 0 (0) | 5 (14) |
| Major mismatch | 0 (0) | 2 (9) | 0 (0) | 2 (6) |
| Bidirectional mismatch | 0 (0) | 1 (4) | 1 (14) | 2 (6) |
| GVH HLA matching, n (%) | ||||
| 5/10 | 3 (60) | 12 (52) | 5 (71) | 20 (57) |
| 6/10 | 2 (40) | 6 (26) | 2 (29) | 10 (29) |
| 7/10 | 0 (0) | 2 (9) | 0 (0) | 2 (6) |
| 8/10 | 0 (0) | 2 (9) | 0 (0) | 2 (6) |
| 10/10 | 0 (0) | 1 (4) | 0 (0) | 1 (3) |
| HVG HLA matching, n (%) | ||||
| 5/10 | 2 (40) | 14 (61) | 4 (57) | 20 (57) |
| 6/10 | 2 (40) | 4 (17) | 2 (29) | 8 (23) |
| 7/10 | 1 (20) | 3 (13) | 1 (14) | 5 (14) |
| 8/10 | 0 (0) | 2 (9) | 0 (0) | 2 (6) |
| Female into male, n (%) | 2 (40) | 3 (13) | 2 (29) | 7 (20) |
| Donor relation, n (%) | ||||
| Father | 2 (40) | 2 (9) | 2 (29) | 6 (17) |
| Mother | 1 (20) | 2 (9) | 2 (29) | 5 (14) |
| Brother | 0 (0) | 7 (30) | 0 (0) | 7 (20) |
| Sister | 2 (40) | 2 (9) | 2 (29) | 6 (17) |
| Son | 0 (0) | 6 (26) | 0 (0) | 6 (17) |
| Daughter | 0 (0) | 1 (4) | 0 (0) | 1 (3) |
| Cousin (male) | 0 (0) | 1 (4) | 1 (14) | 2 (6) |
| Cousin (female) | 0 (0) | 1 (4) | 0 (0) | 1 (3) |
| Nephew | 0 (0) | 1 (4) | 0 (0) | 1 (3) |
| Infused cell dose, median (range) | ||||
| Total nucleated cells (108/kg) | 5.6 (3.6-6.6) | 4.7 (1.8-9.5) | 4.3 (2.8-6.6) | 4.7 (1.8-9.5) |
| CD34+ cells (106/kg) | 7.4 (2.8-8.2) | 5.1 (2.6-11.3) | 3.9 (3.0-7.2) | 4.8 (2.6-11.3) |
| CD3+ cells (107/kg) | 3.9 (3.1-4.0) | 3.3 (1.9-6.7) | 3.7 (2.3-4.9) | 3.4 (1.9-6.7) |
Patient demographics by PTCy DL. DL2 includes patients in both phase 1 and 2. Infused cell doses were based on recipient IBW.
CR, complete remission; HVG, host-versus-graft; MRD, measurable residual disease; PD, progressive disease; SD, stable disease.